ATC | B/G | Ingredients | code | Registration Nb | Name | Dosage | Presentation | Form | Route | Agent | Laboratory | Country | Price | Pharmacist Margin | Stratum | Responsible Party Name | Responsible Party Country | Exch_date | %SUBSIDY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
L01FF03 | BioTech | Durvalumab - 120mg/2.4ml | 10034 | 74319/1 | IMFINZI | 120mg/2.4ml | 1x2.4ml | Injectable solution | Infusion | Omnipharma | Catalent Indiana, LLC | USA | 59,776,110 L.L | 10.71 | E1 | AstraZeneca UK Ltd | UK | 2/5/2024 | 0 |
ATC | B/G | Ingredients | code | Registration Nb | Name | Dosage | Presentation | Form | Route | Agent | Laboratory | Country | Price | Pharmacist Margin | Stratum | Responsible Party Name | Responsible Party Country | Exch_date | %SUBSIDY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
L01FF03 | BioTech | Durvalumab - 120mg/2.4ml | 11728 | 124/1 | IMFINZI | 120mg/2.4ml | 1x2.4ml | Injectable solution | Infusion | Omnipharma | AstraZeneca AB | Sweden | 59,776,110 L.L | 10.71 | E1 | AstraZeneca UK Ltd | UK | 2/5/2024 | 0 |